Analysts Expect Lantheus Holdings Inc (LNTH) Will Post Earnings of $0.16 Per Share
Equities research analysts expect Lantheus Holdings Inc (NASDAQ:LNTH) to report earnings of $0.16 per share for the current quarter, according to Zacks. Two analysts have made estimates for Lantheus’ earnings. The lowest EPS estimate is $0.11 and the highest is $0.20. Lantheus reported earnings per share of $0.18 in the same quarter last year, which would indicate a negative year over year growth rate of 11.1%. The company is scheduled to report its next quarterly earnings results after the market closes on Monday, February 26th.
On average, analysts expect that Lantheus will report full-year earnings of $1.05 per share for the current fiscal year. For the next financial year, analysts expect that the firm will post earnings of $1.29 per share, with EPS estimates ranging from $1.19 to $1.38. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Lantheus.
Several equities research analysts recently issued reports on LNTH shares. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a report on Saturday, January 27th. BidaskClub lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. ValuEngine lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Credit Suisse Group increased their target price on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $24.75.
Hedge funds have recently bought and sold shares of the business. Thrivent Financial For Lutherans bought a new position in Lantheus in the 2nd quarter worth approximately $321,000. Schwab Charles Investment Management Inc. bought a new position in Lantheus in the 2nd quarter worth approximately $770,000. Vanguard Group Inc. boosted its stake in Lantheus by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after purchasing an additional 689,954 shares during the period. BNP Paribas Arbitrage SA boosted its stake in Lantheus by 75.7% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 14,565 shares of the medical equipment provider’s stock worth $259,000 after purchasing an additional 6,274 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Lantheus by 547.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,761 shares of the medical equipment provider’s stock worth $419,000 after purchasing an additional 20,093 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.
Lantheus (NASDAQ:LNTH) traded up $0.20 during midday trading on Friday, hitting $20.55. 131,409 shares of the stock traded hands, compared to its average volume of 289,850. Lantheus has a 12-month low of $9.00 and a 12-month high of $24.45. The stock has a market cap of $763.25, a price-to-earnings ratio of 25.37, a P/E/G ratio of 1.32 and a beta of 0.95. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.
TRADEMARK VIOLATION WARNING: “Analysts Expect Lantheus Holdings Inc (LNTH) Will Post Earnings of $0.16 Per Share” was reported by Marea Informative and is owned by of Marea Informative. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.mareainformativa.com/2018/02/17/analysts-expect-lantheus-holdings-inc-lnth-will-post-earnings-of-0-16-per-share.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.